Evidence map›Paper›PMID 37372948›Full record

ArticleInternational journal of molecular sciences2023

CRISISS: A Novel, Transcriptionally and Post-Translationally Inducible CRISPR/Cas9-Based Cellular Suicide Switch.

Maximilian Amberger, Esther Grueso, Zoltán Ivics

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Ablation of prostaglandin ENature biomedical engineering · 2026
    Article
  2. Review
  3. Review
  4. State-of-the-Art Molecular Genetics and Genomics in Germany.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maximilian AmbergerResearch Center, Division of Hematology, Gene and Cell Therapy, Paul-Ehrlich-Institute, 63225 Langen, Germany.ORCID 0000-0001-8739-4249
Esther GruesoResearch Center, Division of Hematology, Gene and Cell Therapy, Paul-Ehrlich-Institute, 63225 Langen, Germany.ORCID 0000-0002-5365-5129
Zoltán IvicsResearch Center, Division of Hematology, Gene and Cell Therapy, Paul-Ehrlich-Institute, 63225 Langen, Germany.ORCID 0000-0002-7803-6658
Paul Ehrlich Institut · DE

Funding

European Union 754658
6 · The paper itself

Abstract

With the ever-increasing developing rate of gene and cellular therapy applications and growing accessibility due to products receiving regulatory approval, the need for effective and reliable safety mechanisms to prevent or eliminate potentially fatal side effects is of the utmost importance. In this study, we present the CRISPR-induced suicide switch (CRISISS) as a tool to eliminate genetically modified cells in an inducible and highly efficient manner by targeting Cas9 to highly repetitive

Indexed as

CRISPR-Cas SystemsGene EditingAnimalsAnimals, Genetically ModifiedHumansAlu retrotransposonCRISPR/Cas9gene therapySleeping Beauty transposonsuicide genesuicide switch

Identifiers

PMID37372948
PMCPMC10298327
OpenAlexW4379519526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.